167 related articles for article (PubMed ID: 1642695)
1. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Hidaka Y; Eda T; Yonemoto M; Kamei T
Atherosclerosis; 1992 Jul; 95(1):87-94. PubMed ID: 1642695
[TBL] [Abstract][Full Text] [Related]
2. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
3. Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Wajima T; Makita S; Oshima K
Clin Exp Pharmacol Physiol; 2003 Dec; 30(12):958-62. PubMed ID: 14678236
[TBL] [Abstract][Full Text] [Related]
4. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
[TBL] [Abstract][Full Text] [Related]
7. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
8. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
Hidaka Y; Hotta H; Nagata Y; Iwasawa Y; Horie M; Kamei T
J Biol Chem; 1991 Jul; 266(20):13171-7. PubMed ID: 1649182
[TBL] [Abstract][Full Text] [Related]
9. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
[TBL] [Abstract][Full Text] [Related]
10. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
Nagata Y; Hidaka Y; Ishida F; Kamei T
Biochem Pharmacol; 1990 Aug; 40(4):843-50. PubMed ID: 2167097
[TBL] [Abstract][Full Text] [Related]
11. Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration.
Komukai M; Wajima YS; Tashiro J; Shinomiya M; Saito Y; Morisaki N
Scand J Clin Lab Invest; 1999 May; 59(3):159-66. PubMed ID: 10400160
[TBL] [Abstract][Full Text] [Related]
12. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
13. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle.
van Vliet AK; Nègre-Aminou P; van Thiel GC; Bolhuis PA; Cohen LH
Biochem Pharmacol; 1996 Nov; 52(9):1387-92. PubMed ID: 8937448
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
Tesfamariam B; Frohlich BH; Gregg RE
J Cardiovasc Pharmacol; 1999 Jul; 34(1):95-101. PubMed ID: 10413074
[TBL] [Abstract][Full Text] [Related]
16. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR
Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307
[TBL] [Abstract][Full Text] [Related]
17. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Yasunari K; Maeda K; Minami M; Yoshikawa J
Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):937-42. PubMed ID: 11397700
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.
Escobales N; Crespo MJ; Altieri PI; Furilla RA
J Hypertens; 1996 Jan; 14(1):115-21. PubMed ID: 12013483
[TBL] [Abstract][Full Text] [Related]
19. Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model.
Martínez-González J; Badimon L
Eur J Clin Invest; 1996 Nov; 26(11):1023-32. PubMed ID: 8957210
[TBL] [Abstract][Full Text] [Related]
20. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Qin W; Infante J; Wang SR; Infante R
Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
